dc.contributor.author
Dueñas, Nuria
dc.contributor.author
Navarro, Matilde
dc.contributor.author
Sanjuán, Xavier
dc.contributor.author
Ruiz, Núria
dc.contributor.author
Iglesias, Silvia
dc.contributor.author
Matias-Guiu, Xavier, 1958-
dc.contributor.author
Guardiola, Jordi
dc.contributor.author
Kreisler, Esther
dc.contributor.author
Biondo, Sebastiano
dc.contributor.author
González, Sara
dc.contributor.author
Legido, Raquel
dc.contributor.author
Blanco, Ana
dc.contributor.author
Navarro, Silvia
dc.contributor.author
Asiain, Leyre
dc.contributor.author
Santos, Cristina
dc.contributor.author
Capellá, G. (Gabriel)
dc.contributor.author
Pineda, Marta
dc.contributor.author
Brunet, Joan
dc.date.issued
2023-05-24T09:35:17Z
dc.date.issued
2023-11-01T06:10:25Z
dc.date.issued
2022-11-01
dc.date.issued
2023-05-24T09:35:17Z
dc.identifier
https://hdl.handle.net/2445/198386
dc.description.abstract
Background: Lynch syndrome (LS) is the first cause of inherited colorectal cancer (CRC), being responsible for 2-4% of all diagnoses. Identification of affected individuals is important as they have an increased lifetime risk of multiple CRC and other neoplasms, however, LS is consistently underdiagnosed at the population level. We aimed to evaluate the yield of LS screening in CRC in a single-referral centre and to identify the barriers to its effective implementation. Methods: LS screening programme included individuals with CRC < 70 years, multiple CRC, or endometrial cancer at any age. Mismatch repair (MMR) protein immunohistochemistry (IHC) analysis was performed in routine practice on the surgical specimen and, if MLH1 IHC was altered, MLH1 gene promoter methylation was analysed. Results were collected in the CRC multidisciplinary board database. LS suspected individuals (altered MMR IHC without MLH1 promoter methylation) were referred to the Cancer Genetic Counselling Unit (CGCU). If accepted, a genetic study was performed. Two checkpoints were included: review of the pathology data and verification of patient referral by a genetic counsellor. Results: Between 2016 and 2019, 381 individuals were included. MMR IHC analysis was performed in 374/381 (98.2 %) CRC cases and MLH1 promoter methylation in 18/21 (85.7 %). Seventeen of the 20 LS suspected individuals were invited for referral at the CGCU. Two cases were not invited and the remaining patient died of cancer before completion of tumour screening. Fifteen individuals attended and a genetic analysis was performed in 15/20 (75 %) LS suspected individuals. Ten individuals were diagnosed with LS, in concordance with the IHC profile (2.7 % of the total cohort). This led to cascade testing in 58/75 (77.3 %) of the available adult relatives at risk, identifying 26 individuals with LS. Conclusions: Establishing a standardized institutional LS screening programme with checkpoints in the workflow is key to increasing the yield of LS identification.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1016/j.canep.2022.102291
dc.relation
Cancer Epidemiology, 2022, vol. 82, p. 102291
dc.relation
https://doi.org/10.1016/j.canep.2022.102291
dc.rights
cc-by-nc-nd (c) Elsevier, 2022
dc.rights
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Càncer colorectal
dc.subject
Immunohistoquímica
dc.subject
Colorectal cancer
dc.subject
Medical screening
dc.subject
Immunohistochemistry
dc.title
Lessons learnt from the implementation of a colorectal cancer screening programme for lynch syndrome in a tertiary public hospital.
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion